Trevi Therapeutics, Inc. (TRVI)
TRVI price $12.79 -0.04 -0.35%
- Ticker
- TRVI
- Price
- $12.79
- Change
- -0.04 -0.35%
- Market cap
- $1.82B
- P/E
- -37.98
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 67
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with…